PMID- 17559359
OWN - NLM
STAT- MEDLINE
DCOM- 20080305
LR  - 20131121
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 23
IP  - 1
DP  - 2008 Jan
TI  - Comparison of three different second-line quadruple therapies including bismuth 
      subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate 
      Helicobacter pylori with a 14-day standard first-line therapy.
PG  - 42-5
AB  - BACKGROUND AND AIM: Many studies have reported poor results with standard 
      first-line treatment for Helicobacter pylori. Second-line regimens that may 
      overcome bacterial resistance can minimize side-effects and optimize compliance. 
      The aim of this study was to evaluate the efficacy of proton pump inhibitor (PPI) 
      and bismuth subcitrate-based quadruple therapy, after failure of a PPI plus 
      clarithromycin and amoxicillin as first-line therapy. METHODS: Patients who 
      failed to eradicate the infection after initial therapy were randomly separated 
      into three groups. The first group received lansoprazole, bismuth subcitrate, 
      metronidazole and amoxicillin (LBMA); in the second group metronidazole was 
      replaced by tetracycline (LBTA); and the third group was given metronidazole and 
      tetracycline in addition to same doses of lansoprazole and bismuth subcitrate 
      (LBMT). RESULTS: In the LBMA group, the eradication rate was 74.7% and was 
      significantly related to sex, with no relationship to age. In the LBTA group the 
      eradication rate was 81.5% with similar rates in males and females. No relation 
      to sex or age was observed. In the LBMT group the eradication rate was 82.1% with 
      no difference between women and men and it was not related to age, either. 
      Eradication rates in study groups were similar (P > 0.05). CONCLUSION: A-14-day 
      regimen of lansoprazole, bismuth subcitrate and antibiotic pairs, 
      tetracycline-amoxicillin and tetracycline-metronidazole, is an effective 
      quadruple therapy after one failed course of standard triple therapy. The 
      evaluation of tolerability of and compliance with quadruple therapy needs further 
      studies.
FAU - Uygun, Ahmet
AU  - Uygun A
AD  - Department of Gastroenterology, Gulhane Military Medical Academy, School of 
      Medicine, Ankara, Turkey.
FAU - Ozel, A Melih
AU  - Ozel AM
FAU - Yildiz, Oguzhan
AU  - Yildiz O
FAU - Aslan, Murat
AU  - Aslan M
FAU - Yesilova, Zeki
AU  - Yesilova Z
FAU - Erdil, Ahmet
AU  - Erdil A
FAU - Bagci, Sait
AU  - Bagci S
FAU - Gunhan, Omer
AU  - Gunhan O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20070607
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - F8VB5M810T (Tetracycline)
RN  - HS813P8QPX (bismuth tripotassium dicitrate)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Adult
MH  - Amoxicillin/therapeutic use
MH  - Anti-Infective Agents/*therapeutic use
MH  - Dyspepsia/drug therapy/*microbiology
MH  - Female
MH  - Helicobacter Infections/complications/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Organometallic Compounds/*therapeutic use
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Tetracycline/therapeutic use
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Turkey
EDAT- 2007/06/15 09:00
MHDA- 2008/03/06 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2008/03/06 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - JGH4984 [pii]
AID - 10.1111/j.1440-1746.2007.04984.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2008 Jan;23(1):42-5. doi: 
      10.1111/j.1440-1746.2007.04984.x. Epub 2007 Jun 7.